Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)

Background: Grade 3 gastro-entero-pancreatic neuroendocrine tumors (G3 GEP-NET) are poorly characterized in terms of molecular features and response to treatments. Methods: Patients with G3 GEP-NET were included if they received capecitabine and temozolomide (CAPTEM) or oxaliplatin with either 5-flu...

Descrición completa

Detalles Bibliográficos

Principais autores:	Giuseppe Lamberti, Natalie Prinzi, Alberto Bongiovanni, Mariangela Torniai, Elisa Andrini, Dario de Biase, Deborah Malvi, Mirta Mosca, Rossana Berardi, Toni Ibrahim, Sara Pusceddu, Davide Campana
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2023-04-01
Series:	Diagnostics
Assuntos:	NET G3 FOLFOX XELOX CAPTEM NGS
Acceso en liña:	https://www.mdpi.com/2075-4418/13/9/1595
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!